Literature DB >> 21740610

Hepatitis B prevalence in the Turkish population of Arnhem: implications for national screening policy?

C Richter1, G Ter Beest, I Sancak, R Aydinly, K Bulbul, F Laetemia-Tomata, M De Leeuw, T Waegemaekers, C Swanink, E Roovers.   

Abstract

Despite the increased prevalence of hepatitis B and C in most migrant groups in The Netherlands, a national screening policy for these infections is not available. In order to estimate the prevalence of hepatitis B and C in the largest group of first-generation migrants (FGM) in The Netherlands, we conducted a screening project in the Turkish community of Arnhem. In a separate project we identified patients from the target population with chronic hepatitis B and C from hospital records (1990-2008). Educational meetings concerning hepatitis were organized, with all participants being offered a blood screening test. Participants were tested for hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis C virus (anti-HCV). In total 709 persons were tested, a complete dataset was available for 647 patients. We found that 3·0% and 0·4% of Turkish FGM aged >24 years in Arnhem had active hepatitis B, defined as HBsAg positive, and tested positive for anti-HCV, respectively. The hospital records revealed another 32 patients, 28 with hepatitis B and four with hepatitis C representing 0·7% for hepatitis B and 0·1% for hepatitis C in relation to the total number of Turkish FGM in Arnhem. We believe that active hepatitis screening of FGM from Turkey should be part of the national health policy as it will benefit the individual and public health.

Entities:  

Mesh:

Year:  2011        PMID: 21740610     DOI: 10.1017/S0950268811001270

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  17 in total

1.  Effectiveness of Interventions for Hepatitis B and C: A Systematic Review of Vaccination, Screening, Health Promotion and Linkage to Care Within Higher Income Countries.

Authors:  Elizabeth Ortiz; Brighid Scanlon; Amy Mullens; Jo Durham
Journal:  J Community Health       Date:  2020-02

Review 2.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

3.  Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands.

Authors:  C Richter; G Ter Beest; E H Gisolf; P VAN Bentum; C Waegemaekers; C Swanink; E Roovers
Journal:  Epidemiol Infect       Date:  2014-01-07       Impact factor: 4.434

Review 4.  Community-based hepatitis B screening: what works?

Authors:  Monica C Robotin; Jacob George
Journal:  Hepatol Int       Date:  2014-08-01       Impact factor: 6.047

Review 5.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

6.  Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  BMC Health Serv Res       Date:  2017-02-20       Impact factor: 2.655

7.  Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015.

Authors:  Janneke P Bil; Peter Ag Schrooders; Maria Prins; Peter M Kouw; Judith He Klomp; Maarten Scholing; Lutje Phm Huijbregts; Gerard Jb Sonder; Toos Chfm Waegemaekers; Henry Jc de Vries; Wieneke Meijer; Freke R Zuure; Alma Tostmann
Journal:  Euro Surveill       Date:  2018-03

Review 8.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

9.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Authors:  A M Falla; A A Ahmad; E Duffell; T Noori; I K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

10.  Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  Eur J Public Health       Date:  2017-04-01       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.